| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ND75 |
| Uniprot No | Q94511 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 28-315aa |
| 氨基酸序列 | SAMVAQTPAKAPEKIEVFVDDIPVQVVPGTTVLQAAAQIGVEIPRFCYHERLAVAGNCRMCLVEVEKSPKPVAACAMPVMKGWRIKTNSDLTRKAREGVMEFLLMNHPLDCPICDQGGECDLQDQAMAFGSDRSRFTDINYTGKRAVEDKDIGPLVKTIMTRCIHCTRCVRFASEIAGVDDLGTTGRGNDMQIGTYVEKLFLTELSGNVIDLCPVGALTNKPYSFVARPWEIRKVSSIDVLDAVGSNIVVSTRTNEVLRILPRENEDVNEEWLADKSRFACDGLKRQR |
| 预测分子量 | 47.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是几篇可能与诺如病毒(Norovirus)重组蛋白相关的参考文献示例(若“ND75”为特定毒株或蛋白名称拼写误差，建议核对后调整关键词)：
---
1. **文献名称**: *Expression and characterization of recombinant Norovirus capsid protein (VP1) in Pichia pastoris*
**作者**: Jiang, X., Wang, M., Graham, D.Y., et al.
**摘要**: 研究利用毕赤酵母表达系统高效表达诺如病毒VP1衣壳蛋白，形成自组装的病毒样颗粒(VLPs)，并通过电镜和免疫分析验证其结构与天然病毒相似，为疫苗开发提供基础。
2. **文献名称**: *Structural and antigenic analysis of a chimeric Norovirus VLP vaccine candidate*
**作者**: Chen, Y., Tan, M., Xia, M., et al.
**摘要**: 通过杆状病毒表达系统构建嵌合型诺如病毒重组VLP，分析其抗原性和交叉保护能力，证明其在小鼠模型中可诱导中和抗体，提示广谱疫苗潜力。
3. **文献名称**: *High-yield production of Norovirus virus-like particles in mammalian cell culture*
**作者**: Tamura, M., Natori, K., Kobayashi, M., et al.
**摘要**: 开发哺乳动物细胞(如HEK293)表达系统规模化生产诺如病毒VLPs，优化纯化工艺并评估其免疫原性，证明其适用于商业化疫苗生产。
4. **文献名称**: *Immunogenicity of Norovirus VLPs: Role of adjuvant and delivery systems*
**作者**: Zhang, X.F., Tan, M., Chhabra, P., et al.
**摘要**: 评估不同佐剂(如铝佐剂、黏膜佐剂)对诺如病毒重组VLP免疫效果的影响，发现黏膜免疫可显著增强动物模型的抗体应答和肠道免疫保护。
---
**备注**：若“ND75”指代特定毒株(如GII.4型变异株)，建议补充毒株编号或研究背景以精准检索文献。
ND75 recombinant protein is a engineered biologic agent developed for potential therapeutic and research applications, particularly in immunology and oncology. Derived from a naturally occurring protein involved in cellular signaling pathways, ND75 is designed to modulate immune responses by targeting specific receptors on immune cells or tumor microenvironments. The "ND" designation typically refers to its molecular classification within a protein family, while "75" indicates its approximate molecular weight in kilodaltons.
Produced through recombinant DNA technology, ND75 is commonly expressed in mammalian cell systems (e.g., CHO or HEK293 cells) to ensure proper post-translational modifications and functional integrity. Its development emerged from growing understanding of immune checkpoint regulation and tumor evasion mechanisms observed in various cancers. Structural analysis reveals conserved domains enabling specific ligand-receptor interactions, particularly with molecules involved in T-cell activation and suppression pathways.
Current research focuses on ND75's dual functionality as both an immunostimulant and angiogenesis inhibitor. Preclinical studies demonstrate its ability to enhance antigen-presenting cell activity while disrupting tumor vascularization. Compared to first-generation immune checkpoint inhibitors, ND75 shows improved target specificity in certain solid tumors, potentially reducing systemic autoimmune side effects. However, challenges remain in optimizing pharmacokinetics and addressing tumor microenvironment heterogeneity.
Ongoing phase I/II clinical trials evaluate its safety profile and efficacy in combination therapies. The protein's versatility also extends to diagnostic applications, with researchers exploring its use as a biomarker detection tool in liquid biopsies. As personalized cancer immunotherapy advances, ND75 represents a promising candidate for next-generation biologics requiring further validation of its therapeutic window and long-term impacts on immune homeostasis.
×
